Alamandine-(1-5) peptide, pharmaceutical composition and uses

The Alamandine-(1-5) peptide, as a triple agonist of MAS, MrgD, and AT2 receptors, addresses the lack of understanding in existing technologies by demonstrating unique cardiac and vascular effects, offering a therapeutic solution for cardiovascular conditions.

WO2026129014A1PCT designated stage Publication Date: 2026-06-25UNIVERSIDADE FEDERAL DE MINAS GERAIS
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
UNIVERSIDADE FEDERAL DE MINAS GERAIS
Filing Date
2025-12-18
Publication Date
2026-06-25

Smart Images

  • Figure BR2025050598_25062026_PF_FP_ABST
    Figure BR2025050598_25062026_PF_FP_ABST
Patent Text Reader

Abstract

The present technology relates to the alamandine-(1-5) peptide and its use in the manufacture of medicinal products. The peptide acts on the renin-angiotensin system as a triple agonist of the MAS, MrgD and AT2 receptors.
Need to check novelty before this filing date? Find Prior Art